Investors

Welcome to Elicera's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders.

If you need more information or have any questions, please contact Jamal El-Mosleh, CEO.
‍
Phone: +46(0)703 31 90 51
Email: info@elicera.com

Press Releases

August 12, 2022
Regulatory
Elicera Therapeutics announces participation in several industry and partnering conferences
June 2, 2022
Regulatory
Elicera Therapeutics receives 2.5 million Euros in EU funding to fully finance a clinical phase I/II-trial with its CAR T-cell therapy, ELC-301
April 27, 2022
Regulatory
Elicera Therapeutics successfully concludes preclinical proof-of-concept studies for oncolytic virus ELC-201 confirming the proposed mode-of-action
All Press Releases

Corporate Governance

The following sections contain information that are relevant for Elicera's corporate governance.

Articles of AssociationGeneral MeetingBoardManagementAuditorCertified Adviser
Test tubes in a lab environment

The Share

Read about the Share
Scientist working with vaccines in a lab

Financial Reports

Front cover of an Elicera report
Latest report
Q1 report 2022
All Financial Reports

Financial Calendar

See the calendar
Shaking hands in agreement

Analyst Coverage

Read the latest analysis on Elicera here:

Carlsquare - Initial Coverage
All analyses
Audience taking notes
Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Org.nr: 556966-4955
Elicera Therapeutics AB (publ)
World Trade Center Göteborg
Mässans gata 10, floor 7
412 51, Göteborg
info@elicera.com
+46 (0)70-331 90 51‬
Integrity Policy
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.